Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 17/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429695 | 0.87 | MAPKAPK2 (0.48) | MAPKAPK2EGFRALPLKDM4EMEN1 | |
| SCHEMBL425388 | 0.83 | MAPKAPK2 (0.54) | MAPKAPK2EGFRALPLKDM4EMEN1 | |
| SCHEMBL426811 | 0.83 | MAPKAPK2 (0.44) | MAPKAPK2ALPLKDM4EMEN1CLK1 | |
| SCHEMBL428126 | 0.82 | MAPKAPK2 (0.54) | MAPKAPK2EGFRALPLKDM4EMEN1 | |
| SCHEMBL424678 | 0.81 | MAPKAPK2 (0.52) | MAPKAPK2EGFRALPLKDM4EMEN1 | |
| SCHEMBL431688 | 0.81 | MAPKAPK2 (0.55) | MAPKAPK2ALPLKDM4EMEN1CLK1 | |
| SCHEMBL424677 | 0.80 | MAPKAPK2 (0.51) | MAPKAPK2EGFRALPLKDM4EMEN1 | |
| SCHEMBL428125 | 0.79 | MAPKAPK2 (0.53) | MAPKAPK2EGFRALPLKDM4EMEN1 | |
| SCHEMBL426536 | 0.77 | MAPKAPK2 (0.50) | MAPKAPK2EGFRALPLKDM4EMEN1 | |
| SCHEMBL425977 | 0.77 | MAPKAPK2 (0.56) | MAPKAPK2EGFRALPLKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | MAPKAPK2 480/4885EGFR 675/4885ALPL 2689/4885 |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | MAPKAPK2 480/4885EGFR 675/4885ALPL 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.